Skip to main content

NCI-Led Breast, Prostate Cancer Genotyping Study to Use ABI s Technology, Protocol

NEW YORK, April 18 (GenomeWeb News) - The National Cancer Institute's Cohort Consortium will use genotyping technology and protocols from Applied Biosystems to study the genetics of breast and prostate cancer, ABI said today.

 

The project, which combines six large prospective cohort studies that include more than 6,000 breast cancer and 8,000 prostate cancer patients, will make use of ABI's TaqMan SNP genotyping assays and 7,900HT real-time PCR systems to identify inherited gene variants that may contribute to the development of the two cancers. The SNP genotyping assays were designed by Applied Biosystems and will be made public to researchers.

 

Preliminary results from a first study by the Cohort Consortium started in 2003, entitled "Breast and Prostate Cancer and Hormone-Related Gene Variants Study," will be presented this week at the AACR meeting in Anaheim, Calif.

 

The NCI Cohort Consortium is a collaboration involving six American and European prospective cohort studies totaling 897,000 participants, three genomic facilities, and six genotyping centers.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.